Menu

Press Releases

Date Summary View
Toggle Summary RedHill Biopharma Provides Initial Update from its Opaganib COVID-19 Compassionate Use Program in Israel
Objective improvement in first two patients treated with opaganib in Israel who have demonstrated measurable clinical improvement within days of treatment initiation, including decreased supplemental oxygen requirements, decreased C-reactive protein (CRP) levels and increased lymphocyte levels -- ...
View HTML
Toggle Summary RedHill Biopharma Announces Approval of Compassionate Use of Opaganib for COVID-19 in Italy
Authorization of compassionate use granted by the Italian authorities, aided by RedHill’s strategic partner, Cosmo Pharmaceuticals N.V. (SIX: COPN) Approximately 160 patients with life-threatening clinical manifestations planned to be treated in three major hospitals in northern Italy A ...
View HTML
Toggle Summary RedHill Biopharma Announces First COVID-19 Patient Treated with Opaganib in Israel Under Compassionate Use
Compassionate use approved by Israeli Ministry of Health ; Additional patients expected to be treated in the coming days Discussions ongoing in the U.S. and other countries TEL-AVIV, Israel and RALEIGH, N.C. , April 06, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. ...
View HTML
Toggle Summary RedHill Biopharma Completes Acquisition of Movantik® from AstraZeneca
RedHill to promote Movantik ® in the U.S. to expanded call points, including gastroenterologists, primary care physicians and additional specialists, along with Talicia ® and Aemcolo ® Movantik ® generated U.S. net sales of $96 million in 2019 TEL-AVIV, Israel and RALEIGH, N.C. ...
View HTML
Toggle Summary RedHill Biopharma Provides Business Update
TEL-AVIV, Israel and RALEIGH, N.C. , March 25, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company focused on gastrointestinal diseases, today provided a business update on proactive measures being taken with regard to ...
View HTML
Toggle Summary RedHill Biopharma Announces Preferred Position for Talicia® on Express Scripts National Preferred Formulary Effective March 13, 2020
RedHill recently launched Talicia ® in the U.S. , calling on gastroenterologists, primary care physicians and other healthcare providers --- Talicia ® is the first and only FDA-approved rifabutin-based therapy for treatment of H. pylori infection designed as a first-line option to address the high ...
View HTML
Toggle Summary RedHill Biopharma Provides Update on Opaganib (Yeliva®)
       Phase 2 study evaluating RedHill’s proprietary NCE 1 opaganib (Yeliva ® , ABC294640) in prostate cancer initiated at Medical University of South Carolina , supported by an NCI grant ---        Recruitment initiated in second arm of Phase 1/2a study evaluating opaganib in combination with ...
View HTML
Toggle Summary RedHill Biopharma to Present at the Barclays Global Healthcare Conference
TEL-AVIV, Israel and RALEIGH, N.C. , March 10, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company focused on gastrointestinal diseases, today announced that Mr. Dror Ben-Asher , RedHill’s Chief Executive Officer, will ...
View HTML
Toggle Summary RedHill Biopharma Announces U.S. Commercial Launch of Talicia® for H. pylori Infection
Talicia ® is the first and only FDA-approved rifabutin-based therapy for treatment of H. pylori infection designed as a first-line option to address the high and growing H. pylori resistance to clarithromycin -- Talicia ® is targeting an estimated two million U.S. patients treated annually for H. ...
View HTML
Toggle Summary RedHill Biopharma Provides Full-Year 2019 Financial Results and Operational Highlights
Key Highlights: Talicia ®  approved by the FDA for the treatment of H. pylori infection in adults; U.S. launch with RedHill’s sales force expected by mid-March 2020   Acquisition of global rights to Movantik ® (naloxegol) for the treatment of opioid-induced constipation (OIC) in adults from ...
View HTML